Results 121 to 130 of about 2,141 (187)

Effectiveness of Abrocitinib in Atopic Dermatitis Presenting with Hand-Foot Eczema and Nail Dystrophy: A Case Report. [PDF]

Clin Cosmet Investig Dermatol
Ma A, Deng Y.
europepmc   +1 more source

Stapokibart for Facial-Predominant AD-Like Dermatoses: A Retrospective Real-World Case Series Highlighting Response Heterogeneity. [PDF]

Clin Cosmet Investig Dermatol
Zhu Y, Chen J, Wang P, Feng P, Wang X.
europepmc   +1 more source

Efficacy of abrocitinib in patients with atopic dermatitis resistant to Janus kinase inhibitors. [PDF]

Skin Health Dis
Ippoliti E, Gori N, Coscarella G, Antonelli F, Cannizzaro MV, Peris K.   +5 more
europepmc   +1 more source

Real-world effectiveness and safety of 200 mg abrocitinib initiation in Chinese adults with moderate-to-severe atopic dermatitis: a retrospective study. [PDF]

Front Immunol
Lu P, Zhong J, Tan N, Chen A, Cai T, Chen J, Chen S.   +6 more
europepmc   +1 more source

Efficacy and Safety of Abrocitinib for Moderate-to-severe Atopic Dermatitis in Adults: A 52-week Real-world Multicentre StudyIL-AD (Italian Landscape Atopic Dermatitis). [PDF]

Acta Derm Venereol
Pezzolo E, Mariateresa R, Luyo Saboya RA, Malagoli P, Narcisi A, Ferrucci SM, Girolomoni G, Balato A, Manzo Margiotta F, Sciarrone C, Foti C, Gola M, Esposito M, Napolitano M, Gurioli C, Ortoncelli M, Satolli F, Musumeci ML, Savoia P, Amoruso F, Burroni AG, Spigariolo CB, Calzavara-Pinton P, Costanzo A, Gargiulo L, Barei F, Maurelli M, Romanelli M, Veronese F, Tirone B, Fargnoli MC, Patruno C, Ribero S, Vaccino M, Naldi L.   +34 more
europepmc   +1 more source

JAK-STAT pathway-associated skin diseases: a refined functional framework for inflammatory skin diseases. [PDF]

Front Immunol
Li B, Song X, Shan C, He J, Wang Z, Stevanovic K, Zuberbier T, Zhao Z, Zhang L.   +8 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Abrocitinib in Patients with Atopic Dermatitis: A 16-Week Single-Center Retrospective Cohort Study Compared with Upadacitinib and Baricitinib. [PDF]

Dermatol Ther (Heidelb)
Gwag HE, Park M, Park SY, Hong N, Heo SJ, Jung HJ, Park MY, Choi YS, Ahn J.   +8 more
europepmc   +1 more source

Tralokinumab as a cost-saving treatment option for adults and adolescents with moderate-to-severe atopic dermatitis enrolled in US health insurance plans: a budget impact analysis. [PDF]

J Comp Eff Res
Grindley R, Houde L, Sawad AB, Balu S, Schneider S.   +4 more
europepmc   +1 more source

Update of the evidence- and consensus-based S3 guideline on atopic dermatitis: Systemic therapy with biologics or Janus kinase inhibitors and specific aspects of systemic therapy in pregnancy and lactation. [PDF]

Allergol Select
Werfel T, Heratizadeh A, Augustin M, Bangert C, Bauer A, Biedermann T, Brans R, Domröse N, Gieler U, Gießler-Fichtner O, Hamelmann E, Hampe S, Heuer R, Kahle J, Kinberger M, Koch M, Köhler M, Legat F, Nemat K, Neustädter I, Peters EMJ, Radonjic-Hoesli S, Reese I, Schmid-Grendelmeier P, Schmidt-Göhrich UK, Schmitt J, Schnopp C, Schwennesen T, Simon D, Stamos K, Termeer C, Treudler R, von Kiedrowski R, Wagner I, Waßmann-Otto A, Weckmann G, Werner RN, Wollenberg A, Worm M, Ott H.   +39 more
europepmc   +1 more source

Abrocitinib for treatment of solid facial edema

JAAD Case Reports
Axel De Greef, MD, Marie Baeck, MD, PhD
openaire   +3 more sources